Brain-derived neurotrophic factor (BDNF) is a polypeptide belonging to the neurotrophin family of growth factors. It plays a critical role in the survival, differentiation, and synaptic plasticity of neurons throughout the central and peripheral nervous systems[1]. Alongside nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), BDNF constitutes the core of the neurotrophin superfamily, which regulates neural development and maintains adult brain function[2].

Unlike other neurotrophins, BDNF exhibits the highest expression in the brain, particularly in the hippocampus, cortex, and basal forebrain regions. Its activity is tightly regulated by neuronal activity, metabolic state, and environmental stimuli, making it a central mediator of experience-dependent neural plasticity[3].

Discovery & Classification

The neurotrophin concept originated in the 1940s with Rita Levi-Montalcini's discovery of nerve growth factor (NGF). Decades later, in 1982, BDNF was independently isolated and characterized by two research groups: one led by Leonard Reichardt at UCSF, and another by Mu-Ming Poo at Caltech[4].

Neurotrophin Family Members

  • NGF (Neurotrophin-1): Primary regulator of sympathetic and sensory neuron survival
  • BDNF (Neurotrophin-4): Central nervous system development, synaptic plasticity, mood regulation
  • NT-3 (Neurotrophin-3): Motor neuron development, proprioceptive sensory neurons
  • NT-4/5 (Neurotrophin-5): Motor neuron maturation, cortical neuron survival

BDNF is encoded by the BDNF gene located on human chromosome 11p14.1. The gene contains nine exons and multiple promoters, allowing tissue-specific and stimulus-dependent expression patterns[5].

Molecular Structure & Receptors

BDNF is synthesized as a precursor protein (proBDNF, ~50 kDa) that undergoes proteolytic cleavage to produce the mature, biologically active form (~25–30 kDa dimer)span class="citation" data-ref="6">[6]. Both proBDNF and mature BDNF exert distinct, sometimes opposing, effects on neuronal signaling.

BDNF exerts its effects through two primary receptor families:

  • TrkB (Tropomyosin receptor kinase B): A high-affinity tyrosine kinase receptor. Activation triggers intracellular cascades promoting cell survival, growth, and synaptic strengthening[7].
  • p75NTR (pan-neurotrophin receptor): A low-affinity receptor lacking intrinsic kinase activity. When bound to proBDNF, p75NTR can initiate apoptotic signaling pathways, particularly in stressed or injured neurons[8].
The duality of proBDNF and mature BDNF signaling represents a fundamental biological switch between neuronal growth and programmed cell death during development and stress responses.

Biological Functions

Neuronal Survival & Development

During embryonic and postnatal development, BDNF supports the survival of specific neuronal populations, particularly in the hippocampus, cortex, and substantia nigra. It reduces apoptotic signals and promotes axonal guidance and dendritic arborization[9].

Synaptic Plasticity & Learning

BDNF is a key regulator of long-term potentiation (LTP), the cellular basis of learning and memory. Activity-dependent BDNF release strengthens synapses by increasing AMPA receptor trafficking to the postsynaptic membrane and modulating NMDA receptor function[10].

Mood Regulation & Mental Health

Decades of research link reduced BDNF signaling to major depressive disorder (MDD). Chronic stress downregulates BDNF expression in the hippocampus and prefrontal cortex, leading to dendritic atrophy and impaired neurogenesis[11]. Conversely, antidepressant therapies consistently upregulate BDNF levels, restoring synaptic connectivity.

Signaling Pathways

Upon binding to TrkB, BDNF induces receptor dimerization and autophosphorylation of intracellular tyrosine residues. This triggers three major downstream cascades:

  1. MAPK/ERK pathway: Regulates immediate early gene expression, neuronal differentiation, and synaptic plasticity.
  2. PI3K/Akt pathway: Promotes cell survival by inhibiting pro-apoptotic factors (e.g., BAD, caspase-9) and enhancing metabolic activity.
  3. PLCΞ³ pathway: Activates protein kinase C (PKC) and calcium/calmodulin-dependent kinases, modulating neurotransmitter release and gene transcription.

Crosstalk between these pathways ensures coordinated responses to synaptic activity, metabolic demands, and developmental cues[12].

Clinical & Therapeutic Implications

BDNF has emerged as a critical biomarker and therapeutic target across multiple neurological and psychiatric conditions:

  • Neurodegenerative Diseases: Reduced BDNF correlates with cognitive decline in Alzheimer's disease. The Val66Met polymorphism in the BDNF gene is associated with increased Alzheimer's risk and hippocampal volume loss[13].
  • Major Depressive Disorder: Lower serum and cerebrospinal fluid BDNF levels are consistently observed in treatment-resistant depression. Emerging therapies aim to enhance BDNF signaling via exercise, ketone bodies, and novel pharmacological agents.
  • Traumatic Brain Injury & Stroke: Exogenous BDNF delivery or gene therapy approaches show promise in preclinical models by promoting axonal regeneration and reducing neuronal apoptosis.
  • Epilepsy: BDNF upregulation is implicated in kindling and seizure susceptibility, suggesting context-dependent roles in network hyperexcitability.

Current clinical trials are investigating recombinant BDNF, TrkB agonists (e.g., 7,8-DHF), and peripheral-to-central delivery strategies to overcome blood-brain barrier limitations[14].